An improved method for predicting toxicity of the peptides and designing of non-toxic peptides
AHTpin: An in silico platform for predicting, screening and designing of antihypertensive peptides
MBX Biosciences is a clinical-stage biopharmaceutical company developing novel precision peptide therapies for people living with endocrine and metabolic disorders. Its proprietary Precision Endocrine Peptide (PEP) platform engineers long-acting peptide prodrugs, and its pipeline includes canvuparatide (MBX 2109) for chronic hypoparathyroidism…
Parabilis Medicines (formerly FogPharma) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, developing a new class of ultra-tunable alpha-helical peptide therapeutics called Helicons to reach intracellular protein targets long considered undruggable.
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Newark, California and founded in 2006. It discovers and develops peptide-based new chemical entities using a proprietary peptide discovery and engineering platform, targeting rare and prevalent diseases with significant unmet medical need.
MBX Biosciences is a clinical-stage biopharmaceutical company developing novel precision peptide therapies for endocrine and metabolic disorders, built on its proprietary PEPs platform. Lead programs include canvuparatide (MBX 2109) for hypoparathyroidism, plus MBX 4291, MBX 5765, and MBX 6XXX.
XtalPi is an AI-and-quantum-physics drug discovery and materials research platform company with headquarters in Cambridge, Massachusetts and major operations in Beijing, Shanghai, and Shenzhen, publicly listed on the Hong Kong Stock Exchange under stock code 2228.HK.
Add a description, image, and links to the peptide-therapeutics topic page so that developers can more easily learn about it.
To associate your repository with the peptide-therapeutics topic, visit your repo's landing page and select "manage topics."